Mutation of STAT1/3 binding sites in gp130(FXXQ) knock-in mice does not alter hematopoietic stem cell repopulation or self-renewal potential
- PMID: 22754757
- PMCID: PMC3385990
Mutation of STAT1/3 binding sites in gp130(FXXQ) knock-in mice does not alter hematopoietic stem cell repopulation or self-renewal potential
Abstract
Interleukin (IL)-6 family cytokine signaling through gp130 and signal transducer and activator of transcription (STAT) activation is believed important for early hematopoiesis. To determine whether gp130/STAT1/3 physical interaction is required, we compared hematopoietic repopulating activities of embryonic day (E)14.5 fetal liver cells from gp130(FXXQ/FXXQ) knock-in mice, which have four mutated STAT1/3 binding sites. In hematopoietic cells, failure to tyrosine phosphorylate STAT3 by gp130 did not cause any significant effects on myeloid progenitor colony forming units (CFU) in vitro and or on competitive multilineage hematopoietic reconstitution. Serial transplantation of fetal liver (FL) cells was unaffected throughout primary, secondary, and tertiary transplants indicating normal self-renewal capacity. Even gp130(FXXQ/FXXQ) on the background of STAT5 deficiency, with known hematopoietic stem cell (HSC) repopulating dysfunction, did not further impair HSCs beyond that of STAT5 alone. Overall, the defective gp130-mediated STAT1/3 signaling is surprisingly dispensable for HSC function. However, since these mice lack both STAT1/3 binding sites there are several possible explanations for this result and these are discussed.
Figures



Similar articles
-
Hematopoietic abnormalities in mice deficient in gp130-mediated STAT signaling.Exp Hematol. 2002 Nov;30(11):1248-56. doi: 10.1016/s0301-472x(02)00929-3. Exp Hematol. 2002. PMID: 12423677
-
Gab2 promotes hematopoietic stem cell maintenance and self-renewal synergistically with STAT5.PLoS One. 2010 Feb 10;5(2):e9152. doi: 10.1371/journal.pone.0009152. PLoS One. 2010. PMID: 20161778 Free PMC article.
-
Reduced lymphomyeloid repopulating activity from adult bone marrow and fetal liver of mice lacking expression of STAT5.Blood. 2002 Jan 15;99(2):479-87. doi: 10.1182/blood.v99.2.479. Blood. 2002. PMID: 11781228
-
Quantitative assessment of the stem cell self-renewal capacity.Ann N Y Acad Sci. 2001 Jun;938:18-24; discussion 24-5. doi: 10.1111/j.1749-6632.2001.tb03570.x. Ann N Y Acad Sci. 2001. PMID: 11458506 Review.
-
Intracellular proteins and mechanisms involved in the control of gp130/JAK/STAT cytokine signaling.IUBMB Life. 2004 Feb;56(2):83-8. doi: 10.1080/15216540410001668064. IUBMB Life. 2004. PMID: 15085931 Review.
Cited by
-
Acceleration of Bcr-Abl+ leukemia induced by deletion of JAK2.Leukemia. 2014 Sep;28(9):1918-22. doi: 10.1038/leu.2014.152. Epub 2014 May 5. Leukemia. 2014. PMID: 24791858 Free PMC article. No abstract available.
-
Interferon gamma signaling positively regulates hematopoietic stem cell emergence.Dev Cell. 2014 Dec 8;31(5):640-53. doi: 10.1016/j.devcel.2014.11.007. Dev Cell. 2014. PMID: 25490269 Free PMC article.
References
-
- Hirano T, Matsuda T, Nakajima K. Signal transduction through gp130 that is shared among the receptors for the interleukin 6 related cytokine subfamily. Stem Cells. 1994;12:262–277. - PubMed
-
- Boulton TG, Stahl N, Yancopoulos GD. Ciliary neurotrophic factor/leukemia inhibitory factor/interleukin 6/oncostatin M family of cytokines induces tyrosine phosphorylation of a common set of proteins overlapping those induced by other cytokines and growth factors. J Biol Chem. 1994;269:11648–11655. - PubMed
-
- Yoshida K, Taga T, Saito M, Suematsu S, Kumanogoh A, Tanaka T, Fujiwara H, Hirata M, Yamagami T, Nakahata T, Hirabayashi T, Yoneda Y, Tanaka K, Wang WZ, Mori C, Shiota K, Yoshida N, Kishimoto T. Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders. Proc Natl Acad Sci USA. 1996;93:407–411. - PMC - PubMed
-
- Holyoake TL, Freshney MG, McNair L, Parker AN, McKay PJ, Steward WP, Fitzsimons E, Graham GJ, Pragnell IB. Ex vivo expansion with stem cell factor and interleukin-11 augments both short-term recovery posttransplant and the ability to serially transplant marrow. Blood. 1996;87:4589–4595. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous